• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GENZYME CORPORATION(RIDGEFIELD) SYNVISC ONE MOZ

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GENZYME CORPORATION(RIDGEFIELD) SYNVISC ONE MOZ Back to Search Results
Lot Number 7RSL021
Device Problem Microbial Contamination of Device (2303)
Patient Problems Erythema (1840); Arthralgia (2355); Joint Swelling (2356); No Code Available (3191)
Event Date 11/27/2017
Event Type  Injury  
Event Description
Device malfunction [device malfunction], bloody fluid aspirated from right knee [synovial fluid analysis abnormal], increasing pain of both knees [knee pain] ([condition aggravated]), increased swelling of both knees [knee swelling], increased erythema [injection site joint erythema], increased to warmth of both knees [joint warmth], bloody fluid aspirated from right knee [effusion (r) knee]. Case narrative: case was initially submitted via sanofi legacy database and is now being re-distributed to fda at their request. This case is cross referenced with cases: (b)(4) (cluster). This unsolicited case was received on 05-jan-2018 from a pharmacist via health authority of united states (usfda with regulatory reference number: mw5073940). This case involves a patient of unknown demographics age who received treatment with synvisc one and later after one day had increasing pain of both knees, increased swelling of both knees; after 2 days had increased erythema, increased to warmth of both knees, bloody fluid aspirated from right knee (effusion (r) knee and synovial fluid analysis abnormal). Also, device malfunction was identified for the reported lot number. No medical history, past drugs, concomitant medications or concurrent condition was provided. On (b)(6) 2017, the patient initiated treatment with intra-articular synvisc one injection, at dose of 6 ml once (batch number: 7rsl021 and expiration date: 31-may-2020) for osteoarthritis of both knees. On (b)(6) 2017, one day after receiving injection, patient reported: increasing pain and swelling of both knees. On (b)(6) 2017, two days after receiving injection patient reported: increased erythema and warmth to both knees. It was reported that patient was seen in clinic with attempted aspiration. It was reported that minimal serous bloody fluid aspirated from right knee and no fluid aspirated from left knee. It was reported that patient received injection of 5 ml of 1 percent lidocaine/80 mg of methylprednisolone. Patient reported improved symptoms. On follow up visit patient symptoms improved. Corrective treatment: lidocaine, methylprednisolone, bloody fluid aspirated for bloody fluid aspirated from right knee; lidocaine, methylprednisolone for increased to warmth of both knees, increased erythema, increased swelling of both knees and increasing pain of both knees; not reported for other events. Outcome: recovering for all the events. An investigation was initiated as a result of an unexpected increase in the number of labelled adverse events received from the us market for synvisc one, lot 7rsl021. The product met all release testing at time of manufacture in june 2017. Retain samples were retested due to the unexpected increase in adverse events. Higher than expected endotoxin results were obtained. In addition, the presence of microbial contamination was also confirmed. The cause of these events is under investigation. Once this investigation is completed, corrective and preventive actions will be implemented. Seriousness criteria: medically significant for bloody fluid aspirated from right knee; medically significant and required intervention for rest all events. Pharmacovigilance comment: sanofi company comment dated 30-jan-2018: this case concerns a patient who received bilateral synvisc one injections from the recalled lot and after that she had increased knee pain, swelling, erythema and warmth. A temporal relationship can be established with the product administration. Furthermore, the concerned lot number has been identified to have malfunction by the company. Therefore, the causal relationship of the events to the products cannot be excluded.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameSYNVISC ONE
Type of DeviceMOZ
Manufacturer (Section D)
GENZYME CORPORATION(RIDGEFIELD)
1125 pleasantview terrace
ridgefield 07657
Manufacturer (Section G)
GENZYME CORPORATION(RIDGEFIELD)
1125 pleasantview terrace
ridgefield 07657
Manufacturer Contact
heather schiappacasse
55 corporate drive, ms 55b-220
a
bridgewater 08807
MDR Report Key7233933
MDR Text Key211686640
Report Number2246315-2018-00241
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Remedial Action Recall
Type of Report Initial
Report Date 08/26/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/01/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator
Device Expiration Date05/01/2020
Device Lot Number7RSL021
Was Device Available for Evaluation? No
Was the Report Sent to FDA?
Event Location No Information
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 02/01/2018 Patient Sequence Number: 1
-
-